Zealand Pharma — Maj 2022
-
Hele analysen:
-
skal igennem de 100, så tror jeg det initirer flere a
fdækninger -
-
Zealand pumps up its prospects with late-phase rare disease hit
"Zealand Pharma has opened up a new frontier for its struggling glucagon analog dasiglucagon, linking the pump-delivered therapy to improved outcomes in kids with congenital hyperinsulinism (CHI) in a phase 3 clinical trial."
-
tak
-
kan der ikke komme lidt effekt på den fra Bava:9
-
-
Så bliver lommerne fyldt med aktionærens penge. Mon A. Steensberg snart tømmer sin porte monnaie og sætter hånden på koge pladen?
-
Zealand-topchef: “Når stormen har lagt sig, kommer vi ud som et af de stærkeste firmaer”
Fravalget af en salgsstyrke og to potentielle licensaftaler senere i år skal styrke Zealand Pharma til en fremtid som udviklingshus Biotek befinder sig i et uvejr, og værdierne er raslet ned på global
borsen.dk (borsen.dk)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind